Form 4: ProMIS Neurosciences Director Receives Stock Options
Statement of Changes in Beneficial Ownership
Director William Wyman was granted 16,500 stock options in ProMIS Neurosciences Inc. as part of board compensation.
Summary
- Director William Wyman received two grants of stock options totaling 16,500 shares.
- The options have an exercise price of $10.77 per share.
- The options expire on May 20, 2036.
- One grant of 5,500 options vests in full on May 20, 2027.
- A second grant of 11,000 options vests 25% immediately, with the remainder vesting ratably over 36 months.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation with no immediate impact on company fundamentals.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential future dilution of existing shareholders upon the exercise of these options.
Risks
- The value of these options is dependent on the future market performance of ProMIS Neurosciences common shares.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to incentivize long-term oversight and strategic alignment in high-risk, R&D-intensive environments.
Comparison to Industry Standards
- The use of multi-year vesting schedules for director options is consistent with standard corporate governance practices in the biotech industry.
- The exercise price reflects the market value at the time of the grant, adhering to standard regulatory requirements.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of 25% of the 11,000 option grant occurred on May 20, 2026.
- Continued service on the Board is required for the remaining options to vest.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of grant for stock options and earliest transaction date. |
| 05/20/2027 | Full vesting date for the 5,500 option grant. |
| 05/20/2036 | Expiration date for all granted options. |
Keywords
ProMIS Neurosciences, PMN, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.